{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:24:50Z","timestamp":1787624690228,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.clinthera.2007.01.013","type":"journal-article","created":{"date-parts":[[2007,3,24]],"date-time":"2007-03-24T11:05:58Z","timestamp":1174734358000},"page":"26-48","source":"Crossref","is-referenced-by-count":235,"title":["Pregabalin: A novel \u03b3-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders"],"prefix":"10.1016","volume":"29","author":[{"given":"Daniel M.","family":"Tassone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Guyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Nuzum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2007.01.013_bib1","series-title":"FDA approval letter of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy. Department of Health and Human Services","year":"2006"},{"key":"10.1016\/j.clinthera.2007.01.013_bib2","series-title":"FDA approval letter of pregabalin for the management of postherpetic neuralgia","year":"2006"},{"key":"10.1016\/j.clinthera.2007.01.013_bib3","series-title":"FDA approval letter of pregabalin as adjunctive therapy for adult patients with partial onset seizures","year":"2006"},{"key":"10.1016\/j.clinthera.2007.01.013_bib4","series-title":"Pfizer's Lyrica approved for the treatment of generalized anxiety disorder in Europe","year":"2006"},{"key":"10.1016\/j.clinthera.2007.01.013_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0304-3959(03)00173-8","article-title":"Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C","volume":"105","author":"Fehrenbacher","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2007.01.013_bib6","first-page":"P18","article-title":"Metabolic disposition of pregabalin in healthy volunteers","volume":"69","author":"Corrigan","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2007.01.013_bib7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.4088\/JCP.v65n0801","article-title":"Mechanism of action of alpha2delta ligands: Voltage sensitive calcium channel (VSCC) modulators","volume":"65","author":"Stahl","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2007.01.013_bib8","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1345\/aph.1G078","article-title":"Pregabalin: A new neuromodulator with broad therapeutic indications","volume":"39","author":"Shneker","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2007.01.013_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.455003.x","article-title":"Pregabalin pharmacology and its relevance to clinical practice","volume":"45","author":"Ben-Menachem","year":"2004","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2007.01.013_bib10","first-page":"A421","article-title":"Pregabalin pharmacokineticsand safety in healthy volunteers: Results from two phase 1 studies","volume":"54","author":"Bockbrader","year":"2000","journal-title":"Neurology"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2007.01.013_bib11","first-page":"58","article-title":"Pregabalin (CI-1008) single-dose pharmacokinetics and safety\/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses","volume":"39","author":"Busch","year":"1998","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.01.013_bib12","first-page":"47","article-title":"Population pharmacokinetics of pregabalin in healthy volunteers, renally impaired patients and patients with chronic pain","volume":"3","author":"Corrigan","year":"2002","journal-title":"J Pain"},{"key":"10.1016\/j.clinthera.2007.01.013_bib13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/0091270003251119","article-title":"Pharmacokinetics of pregabalin in subjects with various degrees of renal function","volume":"43","author":"Randinitis","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2007.01.013_bib14","series-title":"Presented at: Annual Meeting of the American Psychiatric Association","article-title":"Pharmacokinetic profile of pregabalin: Results of a series of studies","author":"Bockbrader","year":"2004"},{"key":"10.1016\/j.clinthera.2007.01.013_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2004.07.010","article-title":"Progress report on new antiepileptic drugs: A summary of the Seventh Eilat Conference (EILAT VII)","volume":"61","author":"Bialer","year":"2004","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinthera.2007.01.013_bib16","first-page":"P18","article-title":"Metabolic disposition of pregabalin in healthy volunteers","volume":"69","author":"Corrigan","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 8","key":"10.1016\/j.clinthera.2007.01.013_bib17","first-page":"144","article-title":"Pregabalin population pharmacokinetics in patients with refractory partial seizures","volume":"43","author":"Corrigan","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2007.01.013_bib18","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/01.WNL.0000055433.55136.55","article-title":"Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial","volume":"60","author":"Dworkin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.01.013_bib19","series-title":"Lyrica oral capsules [prescribing information]","year":"2006"},{"issue":"Suppl 7","key":"10.1016\/j.clinthera.2007.01.013_bib20","first-page":"84","article-title":"Population pharmacokinetic (PK) analyses of commonly prescribed antiepileptic drugs (AEDs) coadministered with pregabalin (PGB) in adult patients with refractory partial seizures","volume":"42","author":"Bockbrader","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2007.01.013_bib21","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1111\/j.1528-1167.2005.19204.x","article-title":"Pregabalin drug interaction studies: Lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valpro ate in patients with partial epilepsy","volume":"46","author":"Brodie","year":"2005","journal-title":"Epilepsia"},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2007.01.013_bib22","first-page":"A97","article-title":"Pregabalin does not alter the effectiveness of an oral contraceptive","volume":"62","author":"Bockbrader","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.01.013_bib23","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.2337\/diacare.15.12.1926","article-title":"Diabetic neuropathies","volume":"15","author":"Vinik","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2007.01.013_bib24","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1212\/01.WNL.0000140708.62856.72","article-title":"Practice parameter: Treatment of postherpetic neuralgia: An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"63","author":"Dubinsky","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.01.013_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2004.01.001","article-title":"Pregabalin reduces pain and improves sleep and mood disturbances in patients with post herpetic neuralgia: Results of a randomised, placebo-controlled clinical trial","volume":"109","author":"Sabatowski","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2007.01.013_bib26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","article-title":"Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens","volume":"115","author":"Freynhagen","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2007.01.013_bib27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","article-title":"Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebocontrolled trial","volume":"110","author":"Rosenstock","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2007.01.013_bib28","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1212\/01.WNL.0000145767.36287.A1","article-title":"Pregabalin relieves symptoms of painful diabetic neuropa thy: A randomized controlled trial","volume":"63","author":"Lesser","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.01.013_bib29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","article-title":"Relief of painful diabetic peripheral neuropathywith Pregabalin: A randomized, placebo-controlled trial","volume":"6","author":"Richter","year":"2005","journal-title":"J Pain"},{"key":"10.1016\/j.clinthera.2007.01.013_bib30","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","article-title":"Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.01.013_bib31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1586\/17434440.2.2.175","article-title":"Improving the lives of patients with medically refractory epilepsy by electrical stimulation of the nervous system","volume":"2","author":"Murphy","year":"2005","journal-title":"Expert Rev Med Devices"},{"key":"10.1016\/j.clinthera.2007.01.013_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/seiz.1999.0354","article-title":"Vagus nerve stimulation for epilepsy: A review","volume":"9","author":"Binnie","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.clinthera.2007.01.013_bib33_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1017\/S1092852900008464","article-title":"The consequences of uncontrolled epilepsy","volume":"9","author":"Sperling","year":"2004","journal-title":"CNS Spectr"},{"key":"10.1016\/j.clinthera.2007.01.013_bib33_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1017\/S1092852900008464","article-title":"The consequences of uncontrolled epilepsy","volume":"9","author":"Sperling","year":"2004","journal-title":"CNS Spectr"},{"key":"10.1016\/j.clinthera.2007.01.013_bib34","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1212\/01.WNL.0000068024.20285.65","article-title":"Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures","volume":"60","author":"French","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.01.013_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.0013-9580.2004.31203.x","article-title":"Prega-balin add-on treatment: A randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures","volume":"45","author":"Arroyo","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2007.01.013_bib36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/01.WNL.0000150932.48688.BE","article-title":"Safety and effica cy of two pregabalin regimens for add-on treatment of partial epilepsy","volume":"64","author":"Beydoun","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.01.013_bib37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0009-9236(03)00049-3","article-title":"Exposure-response analysis of Pregabalin add-on treatment of patients with refractory partial seizures","volume":"73","author":"Miller","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2007.01.013_bib38","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1528-1167.2005.00341.x","article-title":"Pregabalin add-on treatment in patients with partial seizures: A novel evaluation of flexible-dose and fixed-dose treatment in a doubleblind, placebo-controlled study","volume":"46","author":"Elger","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2007.01.013_bib39","series-title":"Program and abstract of the 56th Annual Meeting of the American Academy of Neurology","article-title":"Pregabalin shows efficacy in reducing simple partial, complex partial, and secondarily generalized seizures","author":"Greiner","year":"2004"},{"key":"10.1016\/j.clinthera.2007.01.013_bib40","first-page":"590","volume":"40","author":"Cramer","year":"1999","journal-title":"New antiepileptic drugs: Comparison of key clinical trials"},{"key":"10.1016\/j.clinthera.2007.01.013_bib41","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","article-title":"Pregabalin for treatment of generalized anxiety disorder: A 4-week, multicenter, double-blind, placebocontrolled trial of pregabalin and alprazolam","volume":"62","author":"Rickels","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2007.01.013_bib42","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","article-title":"Pregabalin in generalized anxiety disorder: A placebo-controlled trial","volume":"160","author":"Pande","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2007.01.013_bib43","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0193-953X(05)70254-9","article-title":"Epidemiology, patterns of comorbidity, and associated disabilities of social phobia","volume":"24","author":"Wittchen","year":"2001","journal-title":"Psychiatr Clin North Am"},{"issue":"2","key":"10.1016\/j.clinthera.2007.01.013_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003592","article-title":"Antidepressants for generalized anxiety disorder","author":"Kapczinski","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.01.013_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1017\/S1092852900006945","article-title":"WCA recommen dations for the long-term treatment of generalized anxiety disorder","volume":"8","author":"Allgulander","year":"2003","journal-title":"CNS Spectr"},{"key":"10.1016\/j.clinthera.2007.01.013_bib46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/j.1440-1614.2004.01423.x","article-title":"Cost-effectiveness of psychological and pharmacological in terventions for generalized anxiety disorder and panic disorder","volume":"38","author":"Heuzenroeder","year":"2004","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.clinthera.2007.01.013_bib47","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1037\/0033-2909.131.5.785","article-title":"Meta-analysis of cognitivebehavior treatments for generalized anxiety disorder: A comparison with pharm acotherapy","volume":"131","author":"Mitte","year":"2005","journal-title":"Psychol Bull"},{"issue":"Suppl 417","key":"10.1016\/j.clinthera.2007.01.013_bib48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1034\/j.1600-0447.108.s417.7.x","article-title":"Pharmacotherapy of social phobia","volume":"108","author":"Davidson","year":"2003","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.clinthera.2007.01.013_bib49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.jcp.0000084032.22282.ff","article-title":"A randomized, double-blind, placebo-controlled, fixed dose, multi center study of pregabalin in patients with generalized anxiety disorder","volume":"23","author":"Feltner","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2007.01.013_bib50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.jcp.0000155820.74832.b0","article-title":"Efficacy of pregabalin in the treatment of generalized anxiety disorder: Double-blind, placebocontrolled comparison of BID versus TID dosing","volume":"25","author":"Pohl","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2007.01.013_bib51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.jcp.0000117423.05703.e7","article-title":"Efficacy of the novel anxiolytic pregabalin in social anxiety disor der: A placebo-controlled, multicenter study","volume":"24","author":"Pande","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2007.01.013_bib52","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archpsyc.1990.01810220015002","article-title":"Long term therapeutic use of benzodiazepines. I. Effect of abrupt discontinuation","volume":"47","author":"Rickels","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2007.01.013_bib53","series-title":"Program and abstract presented at: Annual Meeting of the American Academy of Neurology","article-title":"A double-blind placebocontrolled study to assess the effects of pregabalin on reproductive function in healthy males","author":"Morrell","year":"2004"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807000276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807000276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T17:18:22Z","timestamp":1556299102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291807000276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0149291807000276"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2007.01.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}